GlassScriptPhysician profile
Michael R Lowenthal
NPI 1225031065
$5,189.06
in general payments reported to CMS, 2019-2025
28 companies · $654 in 2025
The $654 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,083 · 2020: $585 · 2021: $960 · 2022: $709 · 2023: $670 · 2024: $527 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,004.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $639.09 | 2019-2025 | |
| Astellas Pharma US INC | $530.83 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $301.70 | 2019-2025 | Gardasil 9, Capvaxive |
| Pfizer INC. | $298.16 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $284.35 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $263.65 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $240.06 | 2019-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.69 | 2019-2022 | |
| Amarin Pharma, INC. | $187.84 | 2019-2022 | |
| Glaxosmithkline, LLC. | $182.73 | 2020-2024 | Arexvy, Shingrix |
| Amgen INC. | $174.29 | 2019-2021 | |
| Esperion Therapeutics, INC. | $170.44 | 2020-2022 | |
| Genentech USA, INC. | $106.03 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $95.54 | 2019-2025 | Spravato |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $84.17 | 2019-2021 | |
| Althera Pharmaceuticals LLC | $72.55 | 2021 | |
| Eisai INC. | $63.41 | 2021 | |
| Hikma Pharmaceuticals USA | $46.21 | 2019-2020 | |
| Allergan, INC. | $43.23 | 2020 | |
| Sanofi Pasteur INC. | $42.99 | 2019-2023 | |
| Renalytix Ai, INC. | $38.62 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Horizon Therapeutics Plc | $25.60 | 2019-2020 | |
| Abbott Laboratories | $21.40 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $19.29 | 2019 | |
| Idorsia Pharmaceuticals US INC | $19.12 | 2023 | Quviviq |
| Dynavax Technologies Corporation | $18.63 | 2024 | Heplisav-B |
| Lilly USA, LLC | $16.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lowenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.